Monoclonal Antibody

Temple of the Golden Pavilion, Kyoto, Japan

Catalent moves into Japan to manufacture regenerative therapy

By Zachary Brennan

Catalent Pharma Solutions has agreed with the Center for iPS Cell Research and Application (CiRA) at Kyoto University in Japan to advance one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans.